Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Meningococcal disease--still a major challenge

S Samuelsson

    Communicable Disease and Public Health
    |November 19, 2002
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Using sentinel surveillance to monitor effectiveness of influenza vaccine is feasible: A pilot study in Denmark.

    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2017
    Same author

    Ascertainment of meningococcal disease in Europe.

    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2017
    Same author

    Comparable effect of recombinant and plasma-derived human fibrinogen concentrate on ex vivo clot formation after cardiac surgery.

    Journal of thrombosis and haemostasis : JTH·2012
    Same author

    Declining incidence of meningococcal disease in Denmark, confirmed by a capture-recapture analysis for 1994 and 2002.

    Epidemiology and infection·2007
    Same author

    Using sentinel surveillance to monitor effectiveness of influenza vaccine is feasible: a pilot study in Denmark.

    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2006
    Same author

    Food does not affect the pharmacokinetics of tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist.

    Journal of clinical pharmacology·2006